References
BEAL, M. F. 2010. Parkinson’s disease: a model dilemma. Nature,466, S8-10.
BERGER, A., LORAIN, S., JOSEPHINE, C., DESROSIERS, M., PECCATE, C., VOIT, T., GARCIA, L., SAHEL, J. A. & BEMELMANS, A. P. 2015. Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa. Mol Ther,23, 918-930.
BEZARD, E. & PRZEDBORSKI, S. 2011. A tale on animal models of Parkinson’s disease. Mov Disord, 26, 993-1002.
BJORKLUND, A., NILSSON, F., MATTSSON, B., HOBAN, D. B. & PARMAR, M. 2022. A Combined alpha-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System. J Parkinsons Dis, 12, 2307-2320.
BURRE, J. 2015. The Synaptic Function of alpha-Synuclein. J Parkinsons Dis, 5, 699-713.
BURRE, J., SHARMA, M. & SUDHOF, T. C. 2018. Cell Biology and Pathophysiology of alpha-Synuclein. Cold Spring Harb Perspect Med, 8.
CEGELSKI, L., PINKNER, J. S., HAMMER, N. D., CUSUMANO, C. K., HUNG, C. S., CHORELL, E., ABERG, V., WALKER, J. N., SEED, P. C., ALMQVIST, F., CHAPMAN, M. R. & HULTGREN, S. J. 2009. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol, 5, 913-9.
CENCI, M. A. & BJORKLUND, A. 2020. Animal models for preclinical Parkinson’s research: An update and critical appraisal. Prog Brain Res, 252, 27-59.
CHERMENINA, M., CHORELL, E., POKRZYWA, M., ANTTI, H., ALMQVIST, F., STROMBERG, I. & WITTUNG-STAFSHEDE, P. 2015. Single injection of small-molecule amyloid accelerator results in cell death of nigral dopamine neurons in mice. NPJ Parkinsons Dis, 1, 15024.
DOWD, E., MONVILLE, C., TORRES, E. M. & DUNNETT, S. B. 2005. The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull, 68, 24-30.
FITZSIMMONS, D. F., MOLONEY, T. C. & DOWD, E. 2006. Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism. Behav Brain Res, 169, 352-5.
HORVATH, I., WEISE, C. F., ANDERSSON, E. K., CHORELL, E., SELLSTEDT, M., BENGTSSON, C., OLOFSSON, A., HULTGREN, S. J., CHAPMAN, M., WOLF-WATZ, M., ALMQVIST, F. & WITTUNG-STAFSHEDE, P. 2012. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation. J Am Chem Soc, 134,3439-44.
KELLY, R., CAIRNS, A. G., ADEN, J., ALMQVIST, F., BEMELMANS, A. P., BROUILLET, E., PATTON, T., MCKERNAN, D. P. & DOWD, E. 2021. The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models. Biomolecules, 11.
KIRIK, D., ANNETT, L. E., BURGER, C., MUZYCZKA, N., MANDEL, R. J. & BJORKLUND, A. 2003. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson’s disease. Proc Natl Acad Sci U S A,100, 2884-9.
KIRIK, D., ROSENBLAD, C., BURGER, C., LUNDBERG, C., JOHANSEN, T. E., MUZYCZKA, N., MANDEL, R. J. & BJORKLUND, A. 2002. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci, 22, 2780-91.
LO BIANCO, C., RIDET, J. L., SCHNEIDER, B. L., DEGLON, N. & AEBISCHER, P. 2002. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci U S A, 99, 10813-8.
MURPHY, J. & MCKERNAN, D. P. 2022. The Effect of Aggregated Alpha Synuclein on Synaptic and Axonal Proteins in Parkinson’s Disease-A Systematic Review. Biomolecules, 12.
OLSEN, L. K., CAIRNS, A. G., ADEN, J., MORIARTY, N., CABRE, S., ALAMILLA, V. R., ALMQVIST, F., DOWD, E. & MCKERNAN, D. P. 2019. Viral mimetic priming enhances alpha-synuclein-induced degeneration: Implications for Parkinson’s disease. Brain Behav Immun,80, 525-535.
OLSSON, M., NIKKHAH, G., BENTLAGE, C. & BJORKLUND, A. 1995. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.J Neurosci, 15, 3863-75.
OUESLATI, A. 2016. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?J Parkinsons Dis, 6, 39-51.
POKRZYWA, M., PAWELEK, K., KUCIA, W. E., SARBAK, S., CHORELL, E., ALMQVIST, F. & WITTUNG-STAFSHEDE, P. 2017. Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson’s disease.PLoS One, 12, e0184117.
POLINSKI, N. K., VOLPICELLI-DALEY, L. A., SORTWELL, C. E., LUK, K. C., CREMADES, N., GOTTLER, L. M., FROULA, J., DUFFY, M. F., LEE, V. M. Y., MARTINEZ, T. N. & DAVE, K. D. 2018. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents. J Parkinsons Dis, 8, 303-322.
SCHALLERT, T., FLEMING, S. M., LEASURE, J. L., TILLERSON, J. L. & BLAND, S. T. 2000. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology,39, 777-87.
SHARMA, M. & BURRE, J. 2023. alpha-Synuclein in synaptic function and dysfunction. Trends Neurosci, 46, 153-166.
SPILLANTINI, M. G., CROWTHER, R. A., JAKES, R., HASEGAWA, M. & GOEDERT, M. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A, 95, 6469-73.
ST MARTIN, J. L., KLUCKEN, J., OUTEIRO, T. F., NGUYEN, P., KELLER-MCGANDY, C., CANTUTI-CASTELVETRI, I., GRAMMATOPOULOS, T. N., STANDAERT, D. G., HYMAN, B. T. & MCLEAN, P. J. 2007. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.J Neurochem, 100, 1449-57.
TAGLIAFERRO, P. & BURKE, R. E. 2016. Retrograde Axonal Degeneration in Parkinson Disease. J Parkinsons Dis, 6, 1-15.
THAKUR, P., BREGER, L. S., LUNDBLAD, M., WAN, O. W., MATTSSON, B., LUK, K. C., LEE, V. M. Y., TROJANOWSKI, J. Q. & BJORKLUND, A. 2017. Modeling Parkinson’s disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain. Proc Natl Acad Sci U S A, 114, E8284-E8293.
TOFARIS, G. K. 2022. Initiation and progression of alpha-synuclein pathology in Parkinson’s disease. Cell Mol Life Sci, 79,210.
TRIGO-DAMAS, I., DEL REY, N. L. & BLESA, J. 2018. Novel models for Parkinson’s disease and their impact on future drug discovery.Expert Opin Drug Discov, 13, 229-239.
UCHIHARA, T. & GIASSON, B. I. 2016. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol,131, 49-73.
VAN DER PERREN, A., TOELEN, J., CARLON, M., VAN DEN HAUTE, C., COUN, F., HEEMAN, B., REUMERS, V., VANDENBERGHE, L. H., WILSON, J. M., DEBYSER, Z. & BAEKELANDT, V. 2011. Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther, 18, 517-27.
VAN DER PERREN, A., VAN DEN HAUTE, C. & BAEKELANDT, V. 2015. Viral vector-based models of Parkinson’s disease. Curr Top Behav Neurosci, 22, 271-301.
VOLPICELLI-DALEY, L. A., KIRIK, D., STOYKA, L. E., STANDAERT, D. G. & HARMS, A. S. 2016. How can rAAV-alpha-synuclein and the fibril alpha-synuclein models advance our understanding of Parkinson’s disease?J Neurochem, 139 Suppl 1, 131-155.
WONG, Y. C., LUK, K., PURTELL, K., BURKE NANNI, S., STOESSL, A. J., TRUDEAU, L. E., YUE, Z., KRAINC, D., OERTEL, W., OBESO, J. A. & VOLPICELLI-DALEY, L. A. 2019. Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals? Mov Disord, 34, 1406-1422.
XU, Y., DENG, Y. & QING, H. 2015. The phosphorylation of alpha-synuclein: development and implication for the mechanism and therapy of the Parkinson’s disease. J Neurochem, 135,4-18.